Diagnosing endometrial hyperplasia: why is it so difficult to agree?
about
Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapyEpithelial membrane protein-2 expression is an early predictor of endometrial cancer development.Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia.Understanding diagnostic variability in breast pathology: lessons learned from an expert consensus review panel.Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasiaThe problem of colliding networks and its relation to cell fusion and cancerProgestin therapy of complex endometrial hyperplasia with and without atypia.Incidence of endometrial hyperplasia.Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history.Management of endometrial precancers.Feasibility of RNA and DNA extraction from fresh pipelle and archival endometrial tissues for use in gene expression and SNP arrays.Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development.Paired boxed gene 1 expression: A single potential biomarker for differentiating endometrial lesions associated with favorable outcomes in patients with endometrial carcinoma.CTCF genetic alterations in endometrial carcinoma are pro-tumorigenic.New classification system of endometrial hyperplasia WHO 2014 and its clinical implications.[Pitfalls in the histopathological diagnostics of endometrial carcinoma and its precursors : Clinically relevant differential diagnoses, avoidance of false positive diagnoses].
P2860
Q34173018-88F796E7-1C1B-44EC-A8A9-C633A018AB9CQ34179949-0112BE3A-C208-498F-879A-ED2CB2168C80Q34718198-FFBF8A19-F359-4DBB-B8C4-ECEEFA35BA32Q35862396-27A1C9DD-B533-4E36-9563-AF1CA0C9128FQ36099979-2A6B5564-64DB-459B-A529-9C288C305251Q36283995-654EDBE4-5F72-420B-BE0F-3631E42F095FQ36379172-7245A22A-5B66-4059-B194-4A655951B9C6Q37187921-FCB3C0D6-02E0-4FF9-8DC2-5905D8381689Q37217843-A76E3FB1-8B34-44E2-B3C1-679752E79E12Q37235846-1B2AD5F4-BCDB-4B1C-B44B-EA9AE2B60943Q37238537-93DED2B3-4ADB-4708-A3BE-EF5777D9E71BQ37300967-4EAC995F-B061-4167-A470-4433C7977E69Q37354444-8E2B28BF-847F-48A2-8F2B-F7195423DDC4Q38844574-FCDD40ED-90A2-4E68-A4A2-6F2A00476377Q41073866-995027AD-D90E-40AF-A43D-7A048C406B1DQ52366406-10CB575B-D809-4DBB-9A23-19FD09A3AA17Q52981800-6E24B2C3-4BE3-4F6D-AB75-0B7B5B058D86
P2860
Diagnosing endometrial hyperplasia: why is it so difficult to agree?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Diagnosing endometrial hyperplasia: why is it so difficult to agree?
@en
Diagnosing endometrial hyperplasia: why is it so difficult to agree?
@nl
type
label
Diagnosing endometrial hyperplasia: why is it so difficult to agree?
@en
Diagnosing endometrial hyperplasia: why is it so difficult to agree?
@nl
prefLabel
Diagnosing endometrial hyperplasia: why is it so difficult to agree?
@en
Diagnosing endometrial hyperplasia: why is it so difficult to agree?
@nl
P2093
P2860
P1476
Diagnosing endometrial hyperplasia: why is it so difficult to agree?
@en
P2093
Carolyn D Jordan
Kathryn M Newton
Kimberly H Allison
Lynda F Voigt
Rochelle L Garcia
Susan D Reed
P2860
P304
P356
10.1097/PAS.0B013E318159A2A0
P407
P577
2008-05-01T00:00:00Z